Next Generation News and Research

RSS

Finland begins implementation of European biomedical research infrastructures

Finland starts the implementation of European biomedical research infrastructures (BMS ESFRIs) by investing in a national effort called Biomedinfra - a joint effort linking to the EU level initiatives in developing biobanking (BBMRI), bioinformatics (ELIXIR), and translational research (EATRIS) infrastructures. This investment follows the 3-year pan-European planning phase, and a Finnish 2 M€ pilot project for Biomedinfra completed in 2010.

20 Jan 2011

BSi and OMJPI enter development agreement for novel neurological and psychiatric disease therapeutics

The Johns Hopkins Brain Science Institute (BSi) announced today that it has entered into an agreement with Ortho-McNeil-Janssen Pharmaceuticals Inc. (OMJPI) to advance the development of novel therapeutics for neurological and psychiatric diseases.

19 Jan 2011

New GORE VIABAHN Endoprosthesis is now available in Europe

W. L. Gore & Associates today announced the European availability of the GORE VIABAHN Endoprosthesis on a lower profile delivery system. The announcement came during the Leipzig Interventional Course in Germany, where European interventionalists gathered to discuss new approaches in treating patients suffering from peripheral artery disease.

19 Jan 2011

Ingenuity and Erasmus enter next-generation sequencing disease research collaboration

Ingenuity® Systems, a leading provider of information solutions for life science researchers, and Erasmus Medical Center, jointly announced a scientific collaboration using next-generation sequencing (NGS) for disease research.

18 Jan 2011

EverFlex+ Self-Expanding Peripheral Stent System is now available in Europe

Covidien, a leading global provider of healthcare products, today announced availability of the EverFlex+™ Self-Expanding Peripheral Stent System in Europe.

18 Jan 2011

MGH researchers discover massive overexpression of DNA sequences in cancer cells

Massachusetts General Hospital Cancer Center researchers have discovered a previously unknown feature of common tumor cells - massive overexpression of certain DNA sequences that do not code for proteins.

14 Jan 2011

FDA approves Cumberland's Acetadote Injection

Cumberland Pharmaceuticals today announced that it has received approval from the U.S. Food and Drug Administration for a new formulation of Acetadote Injection, the Company's product used to treat acetaminophen poisoning.

13 Jan 2011

Next-generation hospital design can improve health and save money

Extra large private hospital rooms with plenty of natural light and artwork may seem like unaffordable luxuries, but new research shows that these and other architecture and design features can improve patient care and in the long run reduce health care expenses. They are among the elements of the “Fable hospital,” an ideal health care facility as conceived and analyzed by leaders in health care and design. Elements of the Fable hospital are being adopted on the ground today, with the imperative to improve quality and value.

13 Jan 2011

Epigenomics concludes feasibility phase in development of improved product concept for Epi proColon

Epigenomics AG, the cancer molecular diagnostic company, today announced that it has concluded the feasibility phase in the development of an improved product concept for Epi proColon, the Company's DNA methylation-based blood test for assistance in the detection of individuals with colorectal cancer.

13 Jan 2011

Pan-European comparative genomics project to develop software suite for gene regulation analysis

Today, CLC bio announced to be heading a pan-European comparative genomics project, COGANGS (Comparative Genomics and Next Generation Sequencing), to develop a software suite, where up to one thousand genomes, can be used as knowledge input in gene regulation analysis.

13 Jan 2011

DNAVision purchases 4 of Life Technologies' NGS platforms

DNAVision, one of European leading genetic analysis service providers, is pleased to announce the purchase of four next-generation sequencing platforms from Life Technologies, including two latest 5500xl SOLiD™ Systems.

13 Jan 2011

Obesity in children today may contribute to 2-5 year decline in life expectancy

For the first time in history, the next generation will not live longer, or even as long, as their parents. "Diseases such as Type II diabetes, high blood pressure, heart conditions and joint deterioration - what were once considered 'adult' diseases - are regularly being diagnosed in children, due to the prevalence of obesity," said Jessica Bartfield, MD, internal medicine and medical weight-loss specialist at Gottlieb Memorial Hospital, part of the Loyola University Health System.

13 Jan 2011

Education for Health to help achieve Healthy People 2020 goals

Launched on December 2, 2010, Healthy People 2020 is an ambitious, science-based, 10-year agenda for improving the health of all Americans. A key component, Education for Health, is an educational roadmap to achieve the Healthy People 2020 goals.

12 Jan 2011

Illumina announces acquisition of Epicentre Biotechnologies

Illumina, today announced that it has acquired Epicentre Biotechnologies, a leading provider of nucleic acid sample preparation reagents and specialty enzymes used in sequencing and microarray applications.

From Illumina, Inc. 12 Jan 2011

Life Technologies announces new DNA sequencing portfolio for lab research

Life Technologies Corporation today announced a series of new product innovations across the company's DNA sequencing portfolio. To date, most sequencing technologies have primarily addressed the needs of researchers in the highest throughput laboratories, limiting widespread accessibility of these powerful next-generation sequencing technologies.

12 Jan 2011

Rib-X raises $20M to support development of broad spectrum antibiotics pipeline

Rib-X Pharmaceuticals, Inc. today announced that the Company has raised $20 million to support ongoing development of the Company's industry-leading broad spectrum antibiotics pipeline, including late-stage clinical development of delafloxacin, which is expected to enter a Phase 2b study in early 2011.

11 Jan 2011

Caliper launches new LabChip Dx system for clinical research laboratories

Caliper Life Sciences, today announced the launch of Caliper's new, innovative LabChip Dx system for use by clinical research laboratories developing molecular diagnostic tests.

11 Jan 2011

AccessClosure launches Mynx Cadence Vascular Closure Device

AccessClosure, the U.S. market leader in extravascular closure devices, announced today the launch of its next generation product, the Mynx Cadence Vascular Closure Device.

11 Jan 2011

QIAGEN to acquire minority stake in Alacris Theranostics

QIAGEN has signed an agreement for the acquisition of a strategic stake in Alacris Theranostics GmbH, a German start-up company using novel technologies to develop individualized cancer treatment strategies based upon a patient's genomic profile, and for the acquisition of an exclusive option to access all biomarkers emerging from this discovery program.

From QIAGEN Manchester Limited 11 Jan 2011

Boston Scientific completes enrollment in Nitinol Stent System trial for treatment of iliac artery disease

Boston Scientific Corporation today announced that it has completed enrollment in the ORION clinical trial, which is designed to evaluate the Company's EPIC™ Self-Expanding Nitinol Stent System for the treatment of iliac artery disease, a form of peripheral artery disease associated with severe leg pain caused by insufficient blood flow to the muscles (claudication).

10 Jan 2011